MCLEAN, Va. / Jul 10, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a healthcare technology, data, and insights company focused on making healthcare more affordable, transparent and fair for all, announced today that it will release its second quarter 2025 financial results on Wednesday, August 6, 2025, and hold its conference call that morning at 8:00 am Eastern Time.
To join the conference call, please pre-register using the link below. Participants who pre-register will receive a calendar invitation with call access details including a unique PIN. Pre-registration may be completed at any time up to and following the call start time.
To pre-register, go to: https://www.netroadshow.com/events/login?show=3b69aeaa&confId=84575.
A live webcast of the conference call can be accessed through the Investor Relations section of the Company’s website at investors.claritev.com/events-and-presentations. Participants should join the webcast ten minutes prior to the start of the conference call. The earnings press release and supplemental slide deck will also be available on this section of the Company’s website.
For those unable to listen to the live conference call, a replay will be available approximately two hours after the call through the webcast archived on the Investor Relations section of the Company’s website. For those requiring operator assistance please dial (404) 975-4839 or (833) 470-1428. The access code is 014186.
About Claritev
Claritev, formerly known as MultiPlan, is a healthcare technology, data, and insights company focused on delivering affordability, transparency, and quality. Led by a team of deeply experienced associates, data scientists, and innovators, Claritev provides cutting-edge solutions and services fueled by multiple data sources and over 40 years of claims repricing experience. Claritev utilizes world-class technology and AI solutions to power a robust enterprise platform that delivers meaningful insights to drive affordability in healthcare, brings price transparency and optimizes networks and benefits design. By focusing on purpose – build solutions that support all key players – including payors, employers, patients, providers and third parties – Claritev aims to make healthcare more accessible and affordable for all. For more information, visit claritev.com.
| Last Trade: | US$29.20 |
| Daily Volume: | 0 |
| Market Cap: | US$472.160M |
November 12, 2025 November 07, 2025 October 08, 2025 August 06, 2025 July 08, 2025 | |

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load